Use of .DELTA.5 androstenes in the treatment of HIV wasting synd

Details Use of .DELTA.5 androstenes in the treatment of HIV wasting synd Use of .DELTA.5 androstenes in the treatment of HIV wasting synd

1997-01-15

1999-03-23

Travers, Russell

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514178, A61K 3156

Patent

active

058859772

ABSTRACT:
HIV-related weight loss, HIV-related cachexia and HIV-related wasting syndrome can be treated by administering therapeutic amounts of the steroid .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3.beta.-acetoxy-7,17 dione, which are readily metabolized in vivo to .DELTA.5 androstene-3.beta.-ol-7,17 dione. Such treatment can be prophylactic, modulatory, ameliorative or curative in nature.

REFERENCES:
patent: 5292730 (1994-03-01), Landy
patent: 5506223 (1996-04-01), Landy et al.
Landy et al. 1995, 123 CA:83832e.
"Oxandrin"brochure, 1995.
Cat et al., "Treatment for HIV Wasting Syndrome," The Annals of Pharmacotherapy, vol. 28, No. 5, pp. 595-597, May 1994.
Coodley et al., "The HIV Wasting Syndrome: A Review," Journal of Acquired Immune Deficiency Syndromes, vol. 7, No. 7, pp. 681-694, 1994.
Grunfeld et al., "Pathophysiology of the AIDS Wasting Syndrome," AIDS Clinical Review, pp. 191-224, 1992.
Kotler, "Wasting Syndrome: Nutritional Support in HIV Infection," AIDS Research and Human Retroviruses, vol. 10, No. 8, pp. 931-934, Aug. 1994.
Nahlen et al., "Wasting Syndrome in the United States," AIDS, vol. 7, No. 2, pp. 183-188, 1993.
Weinroth et al., "Wasting Syndrome in AIDS: Pathophysiologic Mechanisms and Therapeutic Approaches," Infectious Agents and Disease, vol. 4, No. 2, pp. 76-94, 1995.
Zangerle et al., "Weight loss in HIV-1 infection is associated with immune activation," AIDS, vol. 7, No. 2, pp. 175-181, 1993.

Affiliated with

Also associated with

Rating

Use of .DELTA.5 androstenes in the treatment of HIV wasting synd does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of .DELTA.5 androstenes in the treatment of HIV wasting synd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .DELTA.5 androstenes in the treatment of HIV wasting synd will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2125543